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Azidothymidine (AZT) is a reverse transcriptase (RT) inhibitor that efficiently blocks the replication of spumaretroviruses or foamy viruses (FVs).
To more precisely elucidate the mechanism of action of the FV RT enzyme, we generated an AZT-resistant FV in cell culture. Biologically resistant
virus was obtained for simian foamy virus from macaque (SFVmac), which was insensitive to AZTconcentrations of 1 mM, but not for FVs derived
from chimpanzees. Nucleotide sequencing revealed four non-silent mutations in the pol gene. Introduction of these mutations into an infectious
molecular clone identified all changes to be required for the fully AZT-resistant phenotype of SFVmac. The alteration of individual sites showed that
AZT resistance in SFVmac was likely acquired by consecutive acquisition of polmutations in a defined order, because some alterations on their own
did not result in an efficiently replicating virus, neither in the presence nor in the absence of AZT. The introduction of the mutations into the RTof the
closely related prototypic FV (PFV) did not yield an AZT-resistant virus, instead they significantly impaired the viral fitness.
© 2007 Elsevier Inc. All rights reserved.Keywords: Foamy virus; Reverse transcriptase; AZT resistanceIntroduction
Foamy viruses (FVs) constitute one of two subfamilies of
retroviruses and follow a unique replication pathway (for
reviews, see Linial, 2007; Rethwilm, 2003, 2005). Aside from
early studies the comparative analysis of the replication strategy
between spuma- and orthoretroviruses has only recently
focused on the biochemistry of the RT enzyme (Benzair et al.,
1982, 1983; Boyer et al., in press, 2004; Kögel et al., 1995a,b;
Liu et al., 1977; Rinke et al., 2002). Although the character-
ization of bacterially expressed PFV RT revealed many features
common to all retroviruses (Boyer et al., in press, 2004; Kögel
et al., 1995a,b), it was also shown that PFV RT is much more⁎ Corresponding author. Fax: +49 931 201 49553.
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doi:10.1016/j.virol.2007.08.025processive than orthoretroviral enzymes (Rinke et al., 2002).
Furthermore, mutation of the active center of the PFV RT from
YVDD to YMDD did not result in sensitivity to the antire-
troviral drug 3TC, as in human immunodeficiency virus (HIV),
but rendered the virus replication-deficient (Rinke et al., 2002).
These studies indicated that there are similarities and differences
in the biochemistry of the RT enzymes between orthoretro-
viruses and foamy viruses.
A major difference between ortho- and spumaretroviral RT
enzymes consists in the nature of the precursor and the definite
cleavage products of the Pol protein. While in orthoretroviruses,
the enzymatic proteins are cleaved from a Gag-protease (PR)-
Pol precursor into PR, RT/RNaseH, and integrase (IN), FV Pol
cleavage products are processed from an authentic PR-Pol
precursor and cleavage between the PR and RT/RNaseH
subunits does not occur (for a review, see Linial and Eastman,
2003). Thus, the only observed end products of FV Pol precursor
cleavage are the 85-kDa PR-RT/RNaseH and the 40-kDa IN
Table 1
Comparison of biologically selected AZT-resistant virus withmolecularly cloned
derivatives⁎
Virus D3 D6 D9 D12 D15 D18
SK29-KISE −AZT + +++ ++++ c.d. n.d. n.d.
SFVAZTres −AZT + +++ ++++ c.d. n.d. n.d.
BK03QR-ITTK −AZT + +++ ++++ c.d. n.d. n.d.
BK04RG-ITTK −AZT + +++ ++++ c.d. n.d. n.d.
SK29-KISE +AZT (+) (+) (+) – – –
SFVAZTres +AZT + + + ++ +++ ++++
BK03QR-ITTK +AZT + + + ++ +++ ++++
BK04RG-ITTK +AZT + + + ++ +++ ++++
⁎105 BHK/LTR(SFVmac)lacZ cells were infected at a multiplicity of infection
(MOI) of 0.001 with the respective viruses either in the absence (−AZT) or
presence (+AZT) of 50 μM AZT. The cultures were stained for blue cells at the
indicated days after infection and the replication of virus was monitored.
(+), b1% infected cells; +, 1–10% infected cells; ++, 10–25% of cells were
infected; +++, 25–50% infected cells; ++++, more than 50% of the cell culture
was infected; c.d., cell culture was destroyed; n.d., not done. SK29-KISE is the
wild-type molecular clone-derived virus, SFVAZTres is the biologically selected
AZT-resistant virus, BK03QR-ITTK and BK04RG-ITTK are viruses derived
from molecular clones containing the two gag and four pol or only the four pol
gene mutations, respectively.
152 B. Kretzschmar et al. / Virology 370 (2008) 151–157(Flügel and Pfrepper, 2003). This structural feature of FV RT
enzymes probably has an impact on the function that has not
been elucidated in detail yet.
In addition to tenofovir, AZT (zidovudine) is the only RT-
inhibiting drug, which is active against FVs and completely
inhibits PFV replication in cell culture at a concentration as low
as 5 μM (Lee et al., 2006; Moebes et al., 1997; Rosenblum et al.,
2001). Since the understanding of the biochemistry of the FV
RT would greatly profit from the characterization of an AZT-
resistant variant and the understanding of the mechanism of
AZT resistance in orthoretroviruses, namely, human immuno-
deficiency virus (HIV), would mutually profit from studying a
distantly related virus, we attempted to generate and character-
ize AZT-resistant FVs.
Furthermore, based on homology predictions of the PFVand
HIV RT enzyme structures, AZT resistance in PFV has been
suggested to occur by alteration of certain residues that are
known to confer AZT resistance to HIV-1 (Yvon-Groussin et al.,
2001). We also wanted to investigate this possibility because
experimental evidence for this theory does not exist.Fig. 1. Homology of Pol proteins of different FVand HIV-1. The RT regions of know
for SFVmac (X58484 and M33561), PFV (Y07725), the chimpanzee isolate SFVc
(SFVagm; M74895), FV from felines (FFV: AJ564746), bovines (BFV; U94514) anResults
Generation of biologically AZT-resistant FV
To obtain AZT-resistant viruses we cultivated plasmid-
derived PFV, the chimpanzee FV isolate (SFVcpz), and
SFVmac virus stocks on the appropriate indicator cells and
gradually raised the AZT concentration. Although we were
successful in obtaining an SFVmac variant (SFVAZTres) that
was able to replicate in medium containing 1 mM AZT, several
attempts to similarly generate PFV or SFVcpz variants failed
(data not shown).
Genotypic analysis of AZT-resistant SFVmac
The gag and pol genes of SFVAZTres were amplified by
PCR and subjected to nucleotide sequence analysis. In com-
parison with the full-length SFVmac sequence, which was
assembled from subgenomic SFVmac molecular clones (Gen-
bank accession numbers: X58484 and M33561; see Mergia
et al., 1990a,b), six nucleotide alterations leading to amino acid
changes were found. Two of the changes were located in the gag
open reading frame (ORF) and involved R535gag and G596gag,
which were changed to Q and R, respectively. The presence of
these gag mutations in the parental infectious SFVmac clone
together with the pol mutations (as in pBK03QR-ITTK) did not
influence the AZT susceptibility compared with an SFVmac
clone having only the pol residues mutated (as in pBK04RG-
ITTK) (Table 1). We therefore regarded the Gag ORF alterations
as irrelevant for conferring AZT resistance and did not analyze
them further.
Four point mutations involving residues 211 (K211I), 224
(I224T), 345 (S345T), and 350 (E350K) were detected in pol
(Fig. 1). On the nucleic acid level, all alterations leading to these
amino acid changes required only the mutation of single nu-
cleotides. Themutations identified were at codon 211 fromAAA
to ATA, at codon 224 fromATT to ACT, at codon 345 from TCA
to ACA, and at codon 350 from GAA to AAA. One published
complete genomic sequence of SFVmac already harbors a
threonine at position 224 of the Pol protein (Kupiec et al., 1991).
224T would be more consistent with the other primate FV Pol
proteins, which all harbor a threonine in this position (Fig. 1).n FVs relevant to this study were aligned using the Genbank accession numbers
pz (U04327), orangutan FV (SFVora; AJ544579), African green monkey virus
d equines (EFV; AF20190).
Fig. 2. Genome organization of the wild-type and mutant FV Pol open reading frames. The pol gene of SFVmac is shown in the upper panel with the relative location
of the RT active center and the four amino acid residues associated with AZT resistance. The SFVmac mutants representing all possible combinations of the four
mutations are shown in the lower panel together with the approximate levels of AZT resistance deduced from Table 2. The plasmids pBK04-ITTK and pBK64-ITTK
are identical. Plasmid pBK04-ITTKwas made by exchanging a pol gene fragment containing the four mutations and amplified from DNA of cell cultures infected with
SFVAZTres for a corresponding fragment of pSK29-KISE and pBK64-ITTK was made by in vitro mutagenesis. M108 is a PFV mutant with the changed residues
found in SFVAZTres.
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KISE code for an isoleucine at this position. Thus, the wild-type
SFVmac may have a polymorphism at this site. Because we
found I224T in SFVAZTres, we considered I224T as a mutation
associated with AZT resistance.
Biologically selected SFVAZTres was compared with the
parental virus and the virus derived from transfection of cells
with molecular cloned variants bearing all four pol gene muta-
tions. We observed only slight differences in the development of
cell-free virus titers between the molecularly cloned and
uncloned resistant viruses in the absence or presence of AZT
(Table 1). This indicated that the four mutations identified in pol
are sufficient to confer AZT resistance to SFVmac.
Analysis of reconstituted SFVmac molecular clones
To investigate which of the pol gene mutations was res-
ponsible for the resistant phenotype of SFVmac, we generated aFig. 3. SFVmac protein expression. The expression of Gag (pr71/p68) and Pol (pr127
from cells transfected with the indicated plasmids.series of full-length molecular clones in which all possible
combinations of the four mutations found in SFVAZTres were
represented (Fig. 2).
To analyze whether the introduced mutations affected the
stability or other properties of SFVmac Pol protein, we first
investigated the protein expression following transient trans-
fection of 293T cells with the recombinant plasmids in cellular
lysates. As shown in Fig. 3, all mutants were able to express
Gag and Pol proteins to approximately the same level as non-
mutant virus.
AZT resistance of SFVmac mutants
After demonstrating that the altered Pol proteins are ef-
ficiently expressed 293T cells were transfected with the
parental molecular clone or the variants shown in Fig. 2 and
analyzed on the appropriate indicator cells. Due to the peculiar
replication strategy of FVs, namely, reverse transcription taking) proteins was analyzed by immunoblot with polyclonal rabbit antisera in lysates
Table 2
AZT-sensitivity of mutant viruses⁎
Virus 0.0 μM 0.5 μM 5.0 μM 50 μM
SK29-KISE 100% 0.7±0.5% b0.1% b0.1%
BK04-ITTK 117.0±18.4% 84.3±27.8% 71.0±12.7% 34.9±12.9%
BK30-IISE 1.2±1.2% b0.1% b0.1% b0.1%
BK65KTSE 146.5±21.4% 1.2±0.9% b0.1% b0.1%
SK50-KITE 40.0±16.8% 5.6±3.2% 1.1±1.0% b0.1%
SK51-KISK 31.7±8.8% 1.8±0.8% b0.1% b0.1%
BK81-ITSE 2.5±0.6% b0.1% b0.1% b0.1%
BK38-IITE b0.1% b0.1% b0.1% b0.1%
BK31-IISK 23.0±7.9% 0.6±0.5% b0.1% b0.1%
BK78-KTTE 86.7±20.5% 18.7±12.9% 0.5±0.3% b0.1%
BK76-KTSK 175.5±33.9% 8.1±4.5% b0.1% b0.1%
SK39-KITK 20.6±5.5% 10.8±7.5% 3.0±2.1% 1.0±0.6%
BK80-ITTE 7.3±3.6% 4.0±2.7% 1.0±0.8% 0.3±0.2%
BK77-ITSK 33.6±11.3% 3.8±3.0% 0.9±0.5% b0.1%
BK37-IITK 8.6±2.7% 5.9±3.0% 2.8±1.3% 2.0±0.8%
BK79-KTTK 138.2±21.8% 86.9±11.5% 16.4±10.9% 1.4±0.4%
BK64-ITTK 113.0±19.2% 79.3±20.1% 68.8±18.8% 31.3±20.6%
HSRV2 100% 1.1±0.9% 0.4±0.1% b0.1%
M108 1.3±0.1% 0.5±0.1% 0.4±0.1% b0.1%
⁎293T cells were transiently transfected with 10 μg plasmid DNA either in the
absence or presence of the concentrations of AZT indicated. The viral titers in
the cell-free supernatants were determined on the appropriate indicator cells and
are expressed as values relative to SK29-KISE (for SFVmac mutants) or HSRV2
(for the PFV mutant) in the absence of AZT and arbitrarily set to 100%. This
corresponded to cell-free titers of 7×104 in the case of SFVmac and 6.3×104 for
PFV.
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et al., 1999), the production of virus after transfection of cells
and the analysis of cell-free viral titers were performed in the
absence or presence of AZT. As shown in Table 2, we observed
pronounced differences in the replication competence of the
various mutants that argue for a sequential acquisition of
SFVmac pol gene mutations for replication in the presence of
AZT.
The BK38-IITE virus, for instance, which bears the two
mutations leading to K211I and S345T, did not replicate either
in the absence or presence of AZT. Replication was also
severely limited in the BK30-IISE, BK31-IITK, and BK81-
ITSE viruses, whereas BK37-IISK, BK77-ITSK, BK80-ITTE,
SK39-KITK, and SK51-KISK were moderately impaired to
replicate irrespective of the AZT concentrations. All these
mutants have K211 changed to isoleucine in various combina-
tions (the BK viruses) or E350 modified to lysine (the SKFig. 4. Most likely order of mutagenic evenviruses). It is therefore unlikely that either of these changes
occurred first under drug selection. The only single mutation
that was found to result in a moderate drug resistance was that
leading to S345T (SK50-KITE). While conferring partial AZT
resistance, this mutation weakened the virus to replicate in its
absence (Table 2). Subsequent acquisition of I224T, in addition
to S345T (BK78-KTTE), resulted in an enhancement of viral
fitness and replication predominantly at low AZTconcentration.
Alternatively, threonine may be the natural residue at
position 224 in wild-type SFVmac (as discussed above), in
which case the BK78-KTTE virus would be the first variant to
emerge during AZT-induced selective pressure. Since the
K211I variant greatly decreased replication, if it occurred
before E350K (BK80-ITTE in Table 2), BK79-KTTK was
probably the next virus to emerge. BK79-KTTK was able to
replicate at 5 μM AZT and strongly enhanced replication
without the drug. Finally, the resistant virus acquired the
mutation leading to K211I in addition to I224T, S345T, and
E350K (BK64-ITTK). Compared to BK79-KTTK the replica-
tion ability of BK64-ITTK in the absence of AZT was slightly
reduced, however, it was greatly enhanced at higher drug
concentrations (Table 2).
Attempts to create an AZT-resistant PFV
The introduction of the mutations leading to R211I, S345T,
and E350K in M108 of PFV (residue 224 is already a threonine;
see Fig. 1) did not lead to AZT resistance and, compared to the
parental virus (HSRV2), severely reduced the viral fitness in the
absence of AZT (Table 2). However, we cannot formally
exclude the possibility that only one or two alterations of these
residues might induce AZT resistance to PFV, although we
regard this as very unlikely.
Discussion
The results shown here suggest that AZT resistance in
SFVmac was acquired by sequential acquisition of mutations in
the pol gene in the order: wild-type virus -NS345T -N I224T
-NE350K -NK211I (Fig. 4). However, alternative scenarios are
also possible, although less likely. In particular, the position in
the order of events of the mutation leading to I224T appears
variable (see above). The fully resistant virus was found to be
able to replicate at 1 mM AZT. As shown in Table 2 the BK64-ts resulting in AZT-resistant SFVmac.
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of wild-type virus. Thus, the acquisition of the mutations
leading to drug resistance was accompanied by a moderate
reduction of viral fitness.
The inability to obtain AZT-resistant PFV or chimpanzee
foamy virus by gradually raising the drug concentration in the
cell culture medium was surprising. Because SFVmac and PFV
derived from ourmolecular clones replicate to approximately the
same extracellular viral titers (Table 2), we regard it very
unlikely that significant differences in the replication kinetics
between the two parental viruses are responsible for our futile
attempts in generating biologically drug-resistant PFV. Both
viruses, SFVmac and PFV, have been amplified in cell culture
for years. Although FVs are known to be genetically extremely
stable (Switzer et al., 2005; Thümer et al., 2007), the cell culture-
adapted virus does not necessarily reflect the wild-type situation.
However, SFVcpzwasmolecular cloned approximately 1month
after virus isolation (Herchenröder et al., 1994, 1995). This
questions significant changes in the FV RT sequence upon cell
culture replication and points to differences between SFVmac
and FVs of the higher primates in the ability to respond to AZT
drug selection.
In addition, the introduction of the mutations conferring AZT
resistance to SFVmac into the infectious PFV molecular clone
also did not result in a drug-resistant virus. These mutations
resulted in an approximately 70% reduction in viral fitness of
SFVmac (Table 2). The reduction was much more substantial
when the same mutations were introduced into PFV (Table 2).
This may indicate that PFV is, per se, able to mutate into an
AZT-resistant variant, but that the resistant virus lost the ability
to replicate either in the presence or absence of AZT. The reason
for this currently remains unknown. Answers may emerge when
comparative biochemical analyses of PFV, SFVmac, and
SFVAZTres RT enzymes and structural information become
available.
In the HIV system, AZT resistance develops in vivo at least
under the condition of monotherapy very quickly by consecutive
mutations in the pol gene, while there exist only a few reports on
cell culture selection of AZT-resistant HIV from wild-type virus
(Dianzani et al., 1992; Gao et al., 1992; Kellam et al., 1994;
Larder et al., 1991, 1989; Larder and Kemp, 1989; Smith et al.,
1987). Nothing is known yet about the in vivo development of
AZT resistance in FV infections. The biochemical andmolecular
bases of AZT resistance in HIV-1 and HIV-2 have been thor-
oughly studied. In each virus, a different mechanism dominates
in the acquisition of AZT drug resistance (Boyer et al., 2006).
Although HIV-1 preferentially excises AZT from the growing
DNA chain, resistant HIV-2 was reported to discriminate
between the inhibitor AZTTP and TTP during incorporation
(Boyer et al., 2006). Thus, even closely related viruses can make
use of different strategies to develop drug resistance. The
homology between HIV-1 and HIV-2 RTs is around 60% (Boyer
et al., 2006), while it is approximately 90% for PFVand SFVmac
(Kupiec et al., 1991). Therefore, only subtle differences in the
primary amino acid composition of SFVmac and PFV RT en-
zymes are responsible for the inability to generate an AZT-
resistant PFV.The analyses of FV RT enzymes revealed similarities with as
well as differences to orthoretroviral RT enzymes. Our study
shows that differences even exist within the rather homogenous
FV subfamily of retroviruses. In this respect, it would be
interesting to know whether the conversion of the active center
of the FV RT enzyme from YVDD to YMDD, which led to a
replication-deficient PFV (Rinke et al., 2002), would be
tolerated by SFVmac.
Furthermore, our results do not indicate that the residues
actually involved in FVAZT resistance, are those thought pre-
viously (Yvon-Groussin et al., 2001). In particular, the residues
I182, D209, V343, and K347 were modelled to be involved in
PFVAZT resistance. The results presented here do not support
this view, since (i) the residues identified to confer AZT
resistance to SFVmac are different and (ii) AZT-resistant PFVor
SFVcpz could not be generated at all.
Materials and methods
Cells and viruses
BHK/LTR(SFVmac)lacZ (Roy et al., 2003), BHK/LTR
(PFV)lacZ (Schmidt and Rethwilm, 1995) indicator cells, and
293T cells (DuBridge et al., 1987) were cultivated as described
(DuBridge et al., 1987; Roy et al., 2003; Schmidt and
Rethwilm, 1995). After transient transfection of cells with the
proviral plasmids pSFV-1 (Mergia and Wu, 1998), pcHSRV2
(Moebes et al., 1997), or pSFVcpz (Herchenröder et al., 1995)
viruses were cultivated on the appropriate indicator cells which
were stained for β-Gal as reported (Schmidt and Rethwilm,
1995). AZT (Glaxo) was added to the culture medium at the
concentrations indicated in the figures and tables.
To determine the susceptibility to AZT, virus was produced
by transient transfection (48 h) of 293T cells using calcium
phosphate coprecipitation with 10 μg of plasmid DNA in the
absence or presence of the drug (Moebes et al., 1997). Gene
expression was induced using Na-butyrate at a final concen-
tration of 10 mM for 8 h (Heinkelein et al., 1998). The virus
titer in the cell-free supernatant was determined on indicator
cells in the absence or presence of AZT as described (Moebes
et al., 1997). All virus titrations were performed at least three
times. Virus stocks derived from molecular clones were
abbreviated with the plasmid name lacking the “p” or “pc”.
Molecular cloning
The plasmid pSK29-KISE was obtained by treatment of
partially KpnI-digested pSFV-1 (Mergia and Wu, 1998) with T4
polymerase. This eliminated the KpnI restriction site in the
polylinker of the vector backbone.
After amplification and nucleotide sequencing of the
complete gag and pol genes of the biological resistant SFVmac,
a 3.4-kb XhoI/EcoRI fragment harboring the region with the
identified mutations was amplified and inserted into the full-
length proviral clone via a subclone containing a 8.2 kb XbaI/
KpnI fragment. Mutations were introduced into the XhoI/EcoRI
subclone by recombinant PCR following the method of Higuchi
156 B. Kretzschmar et al. / Virology 370 (2008) 151–157(1990) and then introduced back into the full-length clone as
described above. To ease the identification of amino acid
changes in Gag and Pol, relevant residues are indicated after the
plasmid name.
Because PFV already bears a threonine at position 224 of its
pol gene (see below), we constructed a triple mutant (M108) of
pcHSRV2 (Moebes et al., 1997) that contains R211I, S345T,
and E350K. PFV pol gene mutagenesis was carried out by
recombinant PCR (Higuchi, 1990) on a subcloned 1.83-kb
PacI/SwaI fragment of pcHSRV2 before reinsertion into the
full-length molecular clone.
For exclusion of inadvertent nucleotide exchanges all PCR-
generated fragments were sequenced on the level of the full-
length molecular clones. A detailed description of primers used
for mutagenesis, amplification, and sequencing can be found
online at http://viminfo.virologie.uni-wuerzburg.de/onlinema-
terial/Kretzschmar.pdf.
The complete gag and pol open reading frames (ORFs) of
SFVmac were amplified separately and inserted into the
vectors pRSET-A (Invitrogen) and pET28c (Novagen), respec-
tively. The pET28c-SFVpol plasmid was used to delete the
integrase gene via PCR in order to obtain a PR-RT subclone. A
protease active site mutant (D24A) was created thereof by
overlap PCR and transformed into the E. coli strain Rosetta
DE3 (Novagen) for expression and purification of a PR
(D24A)-RT fusion protein. Bacterial proteins were induced and
purified via the C-terminal 6xHis-tag as described (Imrich et
al., 2000) and used to generate polyclonal rabbit antisera at a
commercial facility.
Immunoblotting
After transfection of 293T cells with proviral constructs, Gag
and Pol protein expression in intracellular lysates was analyzed
by immunoblotting with the rabbit Gag and Pol antisera as
described previously (Heinkelein et al., 1998; Imrich et al.,
2000).
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